@nonoinc.ca
NoNO Inc.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
NONO Inc. With an unwavering commitment to making a difference, NONO Inc. At the forefront of their efforts is the Peptide Nerinetide, a revolutionary treatment that is currently being tested in the Global Phase 3 ESCAPE-NEXT trial.
This trial aims to evaluate the effectiveness of Nerinetide in acute ischemic stroke patients, excluding thrombolysis. The completion of enrollment in both the Phase 3 FRONTIER and the Phase 3 ESCAPE-NEXT studies is a significant milestone for the brand, reflecting their dedication to advancing stroke care. With over 12 million people suffering from stroke annually, and alarming mortality and disability rates, NONO Inc.
Their mission is to empower stroke survivors by providing innovative solutions that improve their quality of life. Join NONO Inc
Company Type
Privately Held
Company Size
11-50
Year Founded
2003
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories